JP2007530588A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530588A5
JP2007530588A5 JP2007505213A JP2007505213A JP2007530588A5 JP 2007530588 A5 JP2007530588 A5 JP 2007530588A5 JP 2007505213 A JP2007505213 A JP 2007505213A JP 2007505213 A JP2007505213 A JP 2007505213A JP 2007530588 A5 JP2007530588 A5 JP 2007530588A5
Authority
JP
Japan
Prior art keywords
receptor
coupling agent
antibody
binding specificity
receptor coupling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530588A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009967 external-priority patent/WO2005092927A1/en
Publication of JP2007530588A publication Critical patent/JP2007530588A/ja
Publication of JP2007530588A5 publication Critical patent/JP2007530588A5/ja
Pending legal-status Critical Current

Links

JP2007505213A 2004-03-23 2005-03-23 レセプターカップリング剤およびその治療用途 Pending JP2007530588A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55580504P 2004-03-23 2004-03-23
PCT/US2005/009967 WO2005092927A1 (en) 2004-03-23 2005-03-23 Receptor coupling agents and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2007530588A JP2007530588A (ja) 2007-11-01
JP2007530588A5 true JP2007530588A5 (enExample) 2008-05-08

Family

ID=34968432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505213A Pending JP2007530588A (ja) 2004-03-23 2005-03-23 レセプターカップリング剤およびその治療用途

Country Status (12)

Country Link
US (2) US7799902B2 (enExample)
EP (2) EP1756162A1 (enExample)
JP (1) JP2007530588A (enExample)
KR (1) KR20060132006A (enExample)
CN (1) CN1980957A (enExample)
AU (1) AU2005227322A1 (enExample)
BR (1) BRPI0509201A (enExample)
CA (1) CA2560742A1 (enExample)
IL (1) IL178254A0 (enExample)
NZ (1) NZ550518A (enExample)
SG (1) SG151294A1 (enExample)
WO (1) WO2005092927A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
CN1753692A (zh) * 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
SG151294A1 (en) * 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
GEP20135917B (en) * 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) * 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
CA2773515C (en) * 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
CN103328626B (zh) 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
AU2012315474B2 (en) 2011-09-30 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against TL1a and uses thereof
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
US9872982B2 (en) * 2012-01-10 2018-01-23 University of Pittsburgh—of the Commonwealth System of Higher Education Electroosmotic convection-enhanced delivery system
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US10077298B2 (en) 2012-11-28 2018-09-18 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
ES2900898T3 (es) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
US10562954B2 (en) 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
CA2947157A1 (en) 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
PT3359576T (pt) 2015-10-08 2025-03-27 Zymeworks Bc Inc Constructos de polipeptídeo de ligação a antigénio compreendendo cadeias leves capa e lambda e usos dos mesmos
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
CA3030636A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
JP7245793B2 (ja) 2017-06-30 2023-03-24 ザイムワークス ビーシー インコーポレイテッド 安定化したキメラＦａｂ
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US341393A (en) 1886-05-04 Steam-pump
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE67415T1 (de) 1988-02-16 1991-10-15 Vetter & Co Apotheker Spritze fuer medizinische zwecke.
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0440846T3 (da) 1990-02-07 1993-07-12 Vetter & Co Apotheker Dobbeltkammersprøjte og anvendelsesfremgangsmåde
US5795964A (en) 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
ATE201879T1 (de) 1990-06-27 2001-06-15 Biogen Inc Oberflächenkomplexbildung von lymphotoxin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP0672143B1 (en) 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
IL108776A (en) * 1993-03-11 1999-11-30 Genentech Inc A method of dissolving a cell or inhibiting cell growth, a bispecific molecule that binds FNT-1R and an SAF antibody, a medical preparation that contains it and its use
FI961285L (fi) 1993-10-01 1996-03-20 Immunex Corp CD40:n vasta-aineita
KR960704938A (ko) 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
US5985547A (en) 1994-03-04 1999-11-16 Children's Hospital Of Philadelphia Detection of a mutation in the HLA-DMβ gene in an immunocompromised patient
DK0809510T3 (da) 1995-01-26 2004-10-04 Biogen Inc Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997029110A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Thiophenopyrimidines
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
HUP9904697A3 (en) 1996-10-11 2001-06-28 Bristol Myers Squibb Company P Methods and compositions for immunomodulation
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
EP2003203A1 (en) 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
ES2281126T3 (es) 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
US20040136951A1 (en) 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
US6417328B2 (en) 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
ES2286856T3 (es) 1997-09-12 2007-12-01 Biogen Idec Ma Inc. Receptores train ricos en cisteina.
DK1051187T3 (da) 1998-01-30 2004-03-08 Univ New York Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6437113B1 (en) 1998-03-05 2002-08-20 Tularik Inc. Suppressors of death domains
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
WO1999064461A2 (en) 1998-06-12 1999-12-16 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US6355782B1 (en) 1998-07-09 2002-03-12 Baylor College Of Medicine Hypohidrotic ectodermal dyplasia genes and proteins
WO2000021558A1 (en) 1998-10-09 2000-04-20 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
AU2021800A (en) 1998-12-04 2000-06-26 Schering Corporation Mammalian genes; related reagents
JP2002543151A (ja) 1999-05-04 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
PT1192185E (pt) 1999-06-09 2006-11-30 Genentech Inc Sinergismo de agonista do receptor de apo-2l e cpt-11
AU7494300A (en) 1999-09-15 2001-04-17 Genentech Inc. Apo-2 receptor antibodies
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US20040005314A1 (en) 2001-07-27 2004-01-08 Enrique Escandon Apo-2l receptor agonist and cpt-11 synergism
JP2004508415A (ja) 2000-09-14 2004-03-18 バイオジェン　インコーポレイテッド 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト
EE200300179A (et) 2000-10-13 2003-08-15 Biogen, Inc. Humaniseeritud LT-ß-R-i vastased antikehad
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002066516A2 (en) * 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7662374B2 (en) * 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
CA2461292A1 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
CA2461665A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
WO2003080671A1 (en) 2002-03-21 2003-10-02 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
WO2004000238A2 (en) 2002-03-22 2003-12-31 Tittle Thomas V Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines
CA2482938A1 (en) 2002-04-12 2003-10-23 Human Genome Sciences, Inc. Antibodies that specifically bind to tr2
US20040101915A1 (en) 2002-06-18 2004-05-27 Irm Llc, A Delaware Limited Liability Company Diagnosis and treatment of chemoresistant tumors
JP4574350B2 (ja) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
US6889341B2 (en) 2002-06-28 2005-05-03 Hewlett-Packard Development Company, L.P. Method and apparatus for maintaining data integrity using a system management processor
CA2491480A1 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
BR0316737A (pt) 2002-11-27 2005-12-13 Irm Llc Métodos e composições para induzir apoptose em células cancerosas
WO2004058191A2 (en) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN1753692A (zh) 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药
EP1754713B1 (en) 2003-05-09 2009-02-25 Genentech, Inc. Apo2L (Trail) receptor binding peptides and uses thereof
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
JP4829780B2 (ja) 2004-03-26 2011-12-07 武田薬品工業株式会社 呼吸器疾患の予防・治療剤
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
WO2005123141A2 (en) 2004-06-11 2005-12-29 Board Of Regents, The University Of Texas System Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
EP1786456A1 (en) 2004-06-18 2007-05-23 Genentech, Inc. Use of apo2l receptor agonists and nk cells or nk cell activators
CA2575152A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
RU2410438C2 (ru) 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
CN100427505C (zh) 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
RU2007112929A (ru) 2004-09-08 2008-10-20 Дженентек, Инк. (Us) Способы применения лигандов рецептора смерти и антител к cd20
CN101048428A (zh) 2004-09-08 2007-10-03 健泰科生物技术公司 利用死亡受体配体和cd20抗体的方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Similar Documents

Publication Publication Date Title
JP2007530588A5 (enExample)
JP2018503401A5 (enExample)
Aggarwal et al. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
ES2895552T3 (es) Anticuerpo
JP2007530588A (ja) レセプターカップリング剤およびその治療用途
JP2023062184A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質
Webber et al. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura
JP2018512430A5 (enExample)
KR20200143470A (ko) 항-ror 항체 구조체
RU2017142716A (ru) Конструкции, направленные на комплексы пептида hpv16-e7/мнс, и виды их использования
Held‐Feindt et al. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors
Li et al. Inducible Resistance of Tumor Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2–Mediated Apoptosis by Generation of a Blockade at the Death Domain Function
EA200800696A1 (ru) Полипептиды и антитела
CA2698369A1 (en) Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
Grewal Overview of TNF superfamily: a chest full of potential therapeutic targets
JP2021113240A (ja) Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2011518128A (ja) 腫瘍、炎症性障害および免疫障害の治療のためのｉｌ−４受容体に対する結合剤
Ukrainskaya et al. Death receptors: new opportunities in cancer therapy
JP2018521999A5 (enExample)
JP2019524111A5 (enExample)
JP2024003141A5 (ja) 抗体およびその治療上の使用
WO2005021578A3 (en) A novel chimeric polypeptide and use thereof
Clodi et al. Reed-Sternberg cells and the TNF family of receptors/ligands
Mori et al. Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor
Abe et al. Simple and highly sensitive assay system for TNFR2-mediated soluble-and transmembrane-TNF activity